Eslam E. Fattah-Abd El

`izbat Jamasah Al Gharbiyah, DK 11152, Egypt

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 18 publications

CACNA1C as a Prognostic Biomarker and Therapeutic Target in High-Grade Serous Ovarian Cancer: Clinical Validation and Molecular Dynamics of Nifedipine Blockade.

CACNA1C as a Prognostic Biomarker and Therapeutic Target in High-Grade Serous Ovarian Cancer: Clinical Validation and Molecular Dynamics of Nifedipine Blockade.

Journal: bioRxiv : the preprint server for biology

Published: May 04, 2026

Retraction notice to "Innovative challenge for the inhibition of hepatocellular carcinoma progression by combined targeting of HSP90 and STAT3/HIF-1α signaling" [Biomedicine & Pharmacotherapy 158 (2023) 114196].

Retraction notice to "Innovative challenge for the inhibition of hepatocellular carcinoma progression by combined targeting of HSP90 and STAT3/HIF-1α signaling" [Biomedicine & Pharmacotherapy 158 (2023) 114196].

Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Published: March 21, 2026

The evolution of CAR therapies across oncology and autoimmunity: mechanistic insights and therapeutic innovations.

The evolution of CAR therapies across oncology and autoimmunity: mechanistic insights and therapeutic innovations.

Journal: International immunopharmacology

Published: March 16, 2026

Remodeling the Immune Landscape: How Obesity-Induced SASPs Create a Pro-Tumorigenic Niche.

Remodeling the Immune Landscape: How Obesity-Induced SASPs Create a Pro-Tumorigenic Niche.

Journal: Current obesity reports

Published: March 13, 2026

Neural stem cell delivery of oncolytic CRAd-S-pk7 immunotherapy for stage 3 ovarian cancer: Dose-regimen studies.

Neural stem cell delivery of oncolytic CRAd-S-pk7 immunotherapy for stage 3 ovarian cancer: Dose-regimen studies.

Journal: Molecular therapy. Oncology

Published: October 21, 2025

Dual Modulation of Senescence and Immune Checkpoints by Metformin and Dapagliflozin Attenuates Liver Fibrosis in a Thioacetamide-Induced Rat Model.

Dual Modulation of Senescence and Immune Checkpoints by Metformin and Dapagliflozin Attenuates Liver Fibrosis in a Thioacetamide-Induced Rat Model.

Journal: Advanced pharmaceutical bulletin

Published: August 17, 2025

Tumor lysis syndrome promotes cancer chemoresistance and relapse through AMPK inhibition.

Tumor lysis syndrome promotes cancer chemoresistance and relapse through AMPK inhibition.

Journal: International immunopharmacology

Published: October 18, 2022

Reprograming immune microenvironment modulates CD47 cancer stem cells in hepatocellular carcinoma.

Reprograming immune microenvironment modulates CD47 cancer stem cells in hepatocellular carcinoma.

Journal: International immunopharmacology

Published: October 14, 2022

Targeting HSP47 and HSP70: promising therapeutic approaches in liver fibrosis management.

Targeting HSP47 and HSP70: promising therapeutic approaches in liver fibrosis management.

Journal: Journal of translational medicine

Published: August 09, 2022

Metformin modulate immune fitness in hepatocellular carcinoma: Molecular and cellular approach.

Metformin modulate immune fitness in hepatocellular carcinoma: Molecular and cellular approach.

Journal: International immunopharmacology

Published: April 09, 2022

IDO/kynurenine pathway in cancer: possible therapeutic approaches.

IDO/kynurenine pathway in cancer: possible therapeutic approaches.

Journal: Journal of translational medicine

Published: March 08, 2022

Empagliflozin adjunct with metformin for the inhibition of hepatocellular carcinoma progression: Emerging approach for new application.

Empagliflozin adjunct with metformin for the inhibition of hepatocellular carcinoma progression: Emerging approach for new application.

Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Published: October 11, 2021

Showing 1-12 of 18

Last Updated: 09/26/2026